Clinical Trials Logo

Adjustment Disorders clinical trials

View clinical trials related to Adjustment Disorders.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT04693052 Enrolling by invitation - Stress Clinical Trials

Attitudes Towards Receiving Mental Health Care Using Telehealth During the COVID-19 Pandemic

Start date: December 10, 2020
Phase:
Study type: Observational

The purpose of this study is to collect patients' experiences and feedback to better understand and improve mental health care using telehealth services. This is critically important as telehealth appointments, including both phone and video calls, continue to be offered for regular appointments to reduce in-person interaction as a preventive measure to help control the spread of COVID-19. Studying patients' perceived benefits and challenges of using telehealth services for mental health care will allow us to prioritize improvements to the telehealth experience and potentially, patient adoption of and comfort with remote appointments. This study's results would also inform policy makers and insurance companies about the potential utility of delivering mental health care through telehealth, even beyond the duration of the COVID-19 pandemic.

NCT ID: NCT03334045 Enrolling by invitation - Clinical trials for Adjustment Disorder With Work Inhibition

Neurobiological Effects of Work-related Adjustment Disorder

NeuroWAD
Start date: May 1, 2018
Phase:
Study type: Observational [Patient Registry]

INTRODUCTION: Stress is one of the greatest burdens of our society and often imply impairments in cognitive and emotional functions. The investigators hypothesize that changes in the brain's dopamine(DA)-based mesocorticolimbic projections in patients with work-related stress (adjustment disorder) will manifest in altered glucose metabolism in relation to neural activity and altered DA radiotracer binding potential at neurotransmitter and receptor level. MATERIAL AND METHODS: Subjects and healthy controls undergo neuropsychiatric tests and PET/MR imaging with three tracers: [18F]FDG to measure glucose metabolism as a marker of neural activity, [11C]raclopride to investigate the DA binding potential in the striatum, and [11C]FLB 457 to study possible impaired mesocortical dopaminergic transmission. To demonstrate difference in glucose metabolism ≥2x41 patients/controls are needed. OUTCOME: The investigators expect to find that symptoms of cognitive and motivational/reward deficits could be attributable to changes in frontal lobe and striatal glucose metabolism in >50% of patients and that changes in striatal D2 receptors and impaired mesocortical dopaminergic transmission in the prefrontal cortex are contributing factors. CONCLUSION: This project aims to generate entirely new and objective evidence of stress-induced cerebral illness and provide a basis for in depth research and more rational management of this strenuous disorder.